SARS-CoV-2 Nucleoprotein Antibodies (Monoclonal)

<strong>Retinol Binding Protein (Native Lyophilized)</strong>_x000D_ <strong>Catalog number:</strong> B2010387_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 150 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Appearance:</strong> Clear Solution_x000D_ <strong>Applications:</strong> High affinity rabbit monoclonal antibodies to SARS-CoV-2 Nucleoprotein. These antibodies are highly purified and have been validated in many capture detection systems (such as ELISA, HRP, Biotin and Lateral Flow). Over 20 clones and 15 validated pairs are available._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> SARS-CoV-2 nucleocapsid protein antibody, SARS-CoV-2 NP antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and_x000D_ O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2._x000D_ Glycobiology. 2020 Dec 9;30(12):981-988._x000D_ _x000D_ 2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312._x000D_ _x000D_ 3: Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian_x000D_ S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L,_x000D_ Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel_x000D_ Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034._x000D_ _x000D_ 4: Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD,_x000D_ Takehara KK, Eggenberger J, Hemann EA, Waterman HR, Fahning ML, Chen Y, Hale M,_x000D_ Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, Hamerman JA, King NP, Gale M Jr,_x000D_ Campbell DJ, Rawlings DJ, Pepper M. Functional SARS-CoV-2-Specific Immune Memory_x000D_ Persists after Mild COVID-19. Cell. 2021 Jan 7;184(1):169-183.e17._x000D_ _x000D_ 5: Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin_x000D_ AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP Jr,_x000D_ Bjorkman PJ. SARS-CoV-2 neutralizing antibody structures inform therapeutic_x000D_ strategies. Nature. 2020 Dec;588(7839):682-687._x000D_ _x000D_ 6: Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z,_x000D_ Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W,_x000D_ Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo_x000D_ W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,_x000D_ BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial._x000D_ Lancet Infect Dis. 2021 Jan;21(1):39-51._x000D_ _x000D_ 7: Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z,_x000D_ Cheng L, Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. Molecular_x000D_ Architecture of the SARS-CoV-2 Virus. Cell. 2020 Oct 29;183(3):730-738.e13._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32906143/">8: Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-_x000D_ Ronen Y, Tamir H, Achdout H, Stein D, Israeli O, Beth-Din A, Melamed S, Weiss S,_x000D_ Israely T, Paran N, Schwartz M, Stern-Ginossar N. The coding capacity of SARS-_x000D_ CoV-2. Nature. 2021 Jan;589(7840):125-130. </a>_x000D_ _x000D_ <strong>Products Related to SARS-CoV-2 Nucleoprotein Antibodies:</strong><a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>